IPM Take
Metabolic syndrome is still diagnosed through familiar measurements: waist circumference, blood pressure, glucose, triglycerides and HDL cholesterol.
Researchers are now looking much deeper, including inside the mitochondrial DNA of immune cells.
That could eventually help explain why patients with apparently similar metabolic risk develop very different complications. But precision medicine has a recurring bad habit: discovering a biological association, calling it a biomarker and leaving health systems to work out whether the result changes anything.
This study is valuable because it opens a door. It should not be used to sell a test.
Executive Summary
A pilot cross-sectional study published in Gene Expression examined mitochondrial DNA variability in CD14-positive monocytes from 87 adults: 34 healthy blood donors, 21 patients with obesity and 32 patients with metabolic syndrome. The researchers used next-generation sequencing to identify heteroplasmy, where different mitochondrial DNA variants coexist within the same cell, and homoplasmy, where a variant is present in nearly all mitochondrial DNA copies.
The analysis found associations between mitochondrial DNA variation and several cardiometabolic measurements. Heteroplasmy in protein-coding regions correlated with vascular stenosis and LDL cholesterol. Variation in ribosomal RNA regions correlated with insulin, while low-level variation in the mitochondrial D-loop correlated with fasting blood glucose. Intermediate heteroplasmy was also associated with how strongly monocytes secreted cytokines following laboratory stimulation.
The results do not show that mitochondrial mutations cause metabolic syndrome, atherosclerosis or inflammation. The study was small, conducted at a single institution, cross-sectional and exploratory. Some correlations were modest, and the researchers found no significant association between mitochondrial DNA variability and the expression of the genes they examined.
The authors themselves raise the possibility that some mitochondrial DNA changes may be a consequence of cardiometabolic stress. They suggest that LDL uptake by monocytes and the development of vascular stenosis could increase mitochondrial variability, rather than mitochondrial variation necessarily driving the disease.
This therefore represents an early scientific Signal. It supports larger prospective studies into mitochondrial biomarkers, immunometabolism and personalised risk prediction. It does not support routine mitochondrial sequencing in metabolic syndrome.
Why it matters
- Policymakers and research funders: Precision cardiometabolic research should move beyond single risk factors, but funding must prioritise replication, diverse cohorts and clinical utility rather than biomarker discovery alone.
- Clinicians: The findings are biologically interesting but should not change current diagnosis, prevention or treatment pathways.
- Diagnostics and industry: Any future test would need standardised sampling, sequencing thresholds, external validation and evidence that results improve decisions or outcomes.
- Patients and advocates: Mitochondrial DNA findings should not be interpreted as genetic destiny. The study identifies associations, not a personal prediction of heart disease or diabetes.
- Payers and HTA bodies: Sequencing should not be reimbursed simply because it detects biological variation. A test must show that it leads to better care than existing, inexpensive cardiometabolic measurements.
Metabolic syndrome is diagnosed using measurements that have been available for decades.
- Blood pressure.
- Blood glucose.
- Cholesterol.
- Triglycerides.
- Waist circumference.
These measures are clinically useful, accessible and relatively inexpensive. But they say little about why two patients with similar results may follow very different paths. One develops diabetes. Another develops severe atherosclerosis. A third remains stable for years.
A new pilot study suggests that part of the answer may be written inside the mitochondrial DNA of immune cells.
The research, published in Gene Expression, examined mitochondrial DNA variation in monocytes from adults with metabolic syndrome, obesity and no identified metabolic disease. Monocytes are circulating immune cells involved in inflammation and can migrate into vascular tissue, where they contribute to the development of macrophages and atherosclerotic plaques.
Mitochondria are best known for producing cellular energy, but they also contain their own DNA.
Unlike nuclear DNA, which normally exists in two copies per cell, mitochondrial DNA exists in hundreds or thousands of copies. These copies are not always identical.
When different mitochondrial DNA variants coexist in the same cell, the condition is called heteroplasmy. The proportion of altered copies may influence whether the cell can compensate or whether its function changes. The relevant threshold can differ between tissues, cell types and individual variants.
This makes mitochondrial heteroplasmy scientifically attractive and clinically difficult.
The researchers recruited 87 adults through Immanuel Kant Baltic Federal University in Kaliningrad. The study included 34 healthy blood donors, 21 patients with obesity and 32 patients meeting criteria for metabolic syndrome. CD14-positive monocytes were isolated from blood, and their mitochondrial DNA was sequenced.
The investigators then compared mitochondrial variation with cardiometabolic measurements and laboratory indicators of monocyte behaviour.
Several associations emerged.
Variation in mitochondrial protein-coding regions correlated positively with the degree of vascular stenosis. Other variants correlated with LDL cholesterol, insulin and fasting glucose. Alternative homoplasmic variants were associated with creatinine, blood urea nitrogen, alkaline phosphatase and bilirubin. Intermediate heteroplasmy across the mitochondrial genome was also associated with the cytokine secretion response after monocytes were stimulated with lipopolysaccharide in the laboratory.
The findings connect three areas that cardiometabolic medicine has often treated separately: mitochondrial function, immune-cell activity and conventional metabolic risk.
That is the scientific opportunity.
Mitochondrial dysfunction may contribute to oxidative stress, altered energy production and metabolic inflammation. Monocytes exposed to an unhealthy metabolic environment can acquire a more inflammatory phenotype and participate in adipose-tissue, liver and vascular disease. A mitochondrial signal inside these cells could therefore offer a more dynamic view of disease biology than a conventional cholesterol or glucose measurement alone.
But the most important word in the study is not “mitochondrial.”
It is “pilot.”
Eighty-seven participants are not enough to define a diagnostic biomarker, construct a population screening strategy or predict who will experience a cardiovascular event.
The study was also cross-sectional. Researchers collected biological and clinical data at one point in time. That means they cannot establish which came first.
Did mitochondrial variation contribute to the metabolic disease?
Did metabolic stress damage mitochondrial DNA?
Are both being driven by age, medication, smoking, inflammation, ancestry, diet or another unmeasured factor?
The study cannot answer these questions.
The authors are appropriately cautious. In discussing the association with stenosis, they suggest mitochondrial heteroplasmy may arise from active LDL uptake by monocytes and the biological stress accompanying plaque development, rather than being the original cause of the vascular disease.
That interpretation matters.
A biomarker can play very different roles.
It can indicate inherited susceptibility.
It can reveal current biological damage.
It can predict future disease.
It can monitor treatment response.
Or it can simply correlate with a condition without improving clinical decisions.
These categories are not interchangeable.
Precision medicine often collapses them into one seductive narrative: a molecular difference has been found, therefore a personalised test is coming.
Most molecular findings never complete that journey.
Before mitochondrial heteroplasmy could become clinically useful in metabolic syndrome, researchers would need to replicate the findings in much larger cohorts, across different populations and healthcare settings. The same variants would need to show consistent relationships with disease. Testing methods, laboratory thresholds and quality controls would need to be standardised.
Prospective studies would then need to determine whether mitochondrial variation predicts diabetes, heart attacks, stroke, kidney disease or treatment response beyond information already available from age, blood pressure, glucose, lipids, smoking and body composition.
Even that would not be enough.
A test must lead to an action.
Would a high heteroplasmy result justify more intensive treatment?
Would it change the choice of glucose-lowering medicine?
Would it identify patients who need vascular imaging?
Could it monitor whether weight loss, exercise or medication is improving mitochondrial and immune function?
Until these questions are answered, sequencing produces information without a pathway.
That can be scientifically useful.
Clinically, it can become expensive confusion.
There is also a risk of genetic determinism.
The language of “DNA mutations” can make metabolic disease sound fixed, inherited and inevitable. Mitochondrial heteroplasmy is more complicated. Variants may be inherited, arise over time, differ between tissues and change under biological pressure.
A mitochondrial signal in a monocyte should not become another way to tell patients that their disease was written into their cells and therefore beyond social or policy intervention.
Cardiometabolic disease remains shaped by food environments, poverty, access to prevention, medication affordability, working conditions, physical activity, pollution and the organisation of primary care.
Molecular biology does not erase political biology.
The global burden is already enormous. WHO identifies raised blood pressure, high blood glucose, overweight, obesity and abnormal blood lipids as major metabolic drivers of noncommunicable disease. These are areas where health systems already know what to measure and often know what to do, but fail to deliver prevention and treatment equitably.
The danger is that sophisticated sequencing attracts funding while basic cardiometabolic care remains inaccessible.
That would be precision medicine for research laboratories, not patients.
The study should therefore be read as a biological lead.
It suggests that mitochondrial DNA variation in monocytes may help connect metabolic dysfunction with inflammation and vascular damage. It gives researchers specific associations to test in larger and better-designed studies. It may eventually contribute to risk stratification or treatment monitoring.
But it does not justify screening patients.
It does not prove causation.
It does not replace blood pressure, glucose or lipid control.
The mitochondria may be telling us something important.
Policy should fund the research required to understand the message, while refusing to pretend that an early molecular signal is already a medical answer.
